Forma Therapeutics Holdings Inc. [NASDAQ: FMTX] plunged by -$5.19 during the normal trading session on Friday and reaching a high of $26.25 during the day while it closed the day at $22.86. The company report on June 11, 2021 that Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress.
Clinical results demonstrated durable improvement in hematologic and hemolytic markers, supporting the potential for improvement of red blood cell functional health in those with sickle cell disease.
Initial results from an open-label extension cohort showed sustained hemoglobin increase of >1g/dL in 88% (7 of 8) of patients dosed for at least two and up to 12 weeks, as well as favorable tolerability profile.
Forma Therapeutics Holdings Inc. stock has also loss -19.87% of its value over the past 7 days. However, FMTX stock has declined by -34.89% in the 3 months of the year. Over the past six months meanwhile, it has lost -55.25% and lost -34.50% year-on date.
The market cap for FMTX stock reached $1.33 billion, with 47.30 million shares outstanding and 43.56 million shares in the current float. Compared to the average trading volume of 406.86K shares, FMTX reached a trading volume of 1375586 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Forma Therapeutics Holdings Inc. [FMTX]:
H.C. Wainwright have made an estimate for Forma Therapeutics Holdings Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 31, 2021. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on February 17, 2021, representing the official price target for Forma Therapeutics Holdings Inc. stock. Previously, the target price had yet another raise to $53, while H.C. Wainwright analysts kept a Buy rating on FMTX stock.
The Average True Range (ATR) for Forma Therapeutics Holdings Inc. is set at 2.15 The Price to Book ratio for the last quarter was 1.75, with the Price to Cash per share for the same quarter was set at 9.47.
FMTX stock trade performance evaluation
Forma Therapeutics Holdings Inc. [FMTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.87. With this latest performance, FMTX shares dropped by -12.51% in over the last four-week period, additionally sinking by -55.25% over the last 6 months.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FMTX stock in for the last two-week period is set at 33.12, with the RSI for the last a single of trading hit 26.93, and the three-weeks RSI is set at 36.83 for Forma Therapeutics Holdings Inc. [FMTX]. The present Moving Average for the last 50 days of trading for this stock 27.26, while it was recorded at 28.28 for the last single week of trading, and 37.27 for the last 200 days.
Forma Therapeutics Holdings Inc. [FMTX]: An insightful look at the core fundamentals
Return on Total Capital for FMTX is now -36.10, given the latest momentum, and Return on Invested Capital for the company is -17.50. Return on Equity for this stock declined to -17.50, with Return on Assets sitting at -16.30.
Reflecting on the efficiency of the workforce at the company, Forma Therapeutics Holdings Inc. [FMTX] managed to generate an average of -$658,075 per employee.Forma Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 20.10 and a Current Ratio set at 20.10.
Earnings per share (EPS) analysis for Forma Therapeutics Holdings Inc. [FMTX] stock
With the latest financial reports released by the company, Forma Therapeutics Holdings Inc. posted -4.58/share EPS, while the average EPS was predicted by analysts to be reported at -0.74/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -518.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FMTX.
Forma Therapeutics Holdings Inc. [FMTX]: Insider Ownership positions
There are presently around $926 million, or 91.50% of FMTX stock, in the hands of institutional investors. The top three institutional holders of FMTX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 9,011,651, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; FMR LLC, holding 4,969,969 shares of the stock with an approximate value of $113.61 million in FMTX stocks shares; and CORMORANT ASSET MANAGEMENT, LP, currently with $107.9 million in FMTX stock with ownership of nearly 5.83% of the company’s market capitalization.
Positions in Forma Therapeutics Holdings Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 55 institutional holders increased their position in Forma Therapeutics Holdings Inc. [NASDAQ:FMTX] by around 5,734,859 shares. Additionally, 30 investors decreased positions by around 2,184,985 shares, while 13 investors held positions by with 32,602,843 shares. The mentioned changes placed institutional holdings at 40,522,687 shares, according to the latest SEC report filing. FMTX stock had 7 new institutional investments in for a total of 130,990 shares, while 12 institutional investors sold positions of 507,040 shares during the same period.